Related Experiment Video
Updated: Oct 12, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
The Pathogenic Role of Long Non-coding RNA H19 in Atherosclerosis via the miR-146a-5p/ANGPTL4 Pathway
Shi-Feng Huang1, Guifang Zhao1, Xiao-Fei Peng2
1Qingyuan People's Hospital, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan, China.
Insights
The long non-coding RNA H19 promotes atherosclerosis by increasing lipid accumulation in macrophages. Targeting H19 may offer a new therapeutic strategy for treating cardiovascular disease.
Area of Science:
- Molecular Biology
- Cardiovascular Research
- RNA Biology
Background:
- Aberrant expression of long non-coding RNA (lncRNA) H19 is implicated in cardiovascular disease.
- The specific role of lncRNA H19 in atherosclerosis remains largely unknown.
- Understanding lncRNA H19's function is crucial for developing novel therapeutic strategies.
Purpose of the Study:
- To investigate the impact of lncRNA H19 on atherogenesis.
- To elucidate the underlying molecular mechanisms by which lncRNA H19 influences atherosclerosis.
- To explore the potential of targeting lncRNA H19 as a therapeutic intervention.
Main Methods:
- Analysis of lncRNA H19 expression in mouse models of atherosclerosis and human cell lines.
- In vivo studies using adeno-associated virus (AAV)-mediated gene transfer in apoE knockout mice.
- Assessment of atherosclerotic plaque area, lipid accumulation, and molecular markers (miR-146a-5p, ANGPTL4).
Main Results:
- lncRNA H19 expression was significantly elevated in atherosclerotic conditions.
- Overexpression of lncRNA H19 exacerbated atherosclerosis and promoted lipid accumulation in macrophages.
- lncRNA H19 upregulated ANGPTL4 by inhibiting miR-146a-5p, thereby promoting lipid accumulation.
Conclusions:
- lncRNA H19 plays a critical role in promoting lipid accumulation and aggravating atherosclerosis progression.
- The miR-146a-5p/ANGPTL4 pathway is a key mechanism through which lncRNA H19 exerts its effects.
- Targeting lncRNA H19 presents a promising therapeutic avenue for atherosclerotic diseases.
Abstract:
The abnormally expressed long non-coding RNA (lncRNA) H19 has a crucial function in the development and progression of cardiovascular disease; however, its role in atherosclerosis is yet to be known. We aimed to examine the impacts of lncRNA H19 on atherogenesis as well as the involved mechanism. The outcomes from this research illustrated that the expression of lncRNA H19 was elevated in mouse blood and aorta with lipid-loaded macrophages and atherosclerosis. Adeno-associated virus (AAV)-mediated lncRNA H19 overexpression significantly increased the atherosclerotic plaque area in apoE-/- mice supplied with a Western diet. The upregulation of lncRNA H19 decreased the miR-146a-5p expression but increased the levels of ANGPTL4 in mouse blood and aorta and THP-1 cells. Furthermore, lncRNA H19 overexpression promoted lipid accumulation in oxidized low-density lipoprotein (ox-LDL)-induced THP-1 macrophages. However, the knockdown of lncRNA H19 served as a protection against atherosclerosis in apoE-/- mice and lowered the accumulation of lipids in ox-LDL-induced THP-1 macrophages. lncRNA H19 promoted the expression of ANGPTL4 via competitively binding to miR-146a-5p, thus promoting lipid accumulation in atherosclerosis. These findings altogether demonstrated that lncRNA H19 facilitated the accumulation of lipid in macrophages and aggravated the progression of atherosclerosis through the miR-146a-5p/ANGPTL4 pathway. Targeting lncRNA H19 might be an auspicious therapeutic approach for preventing and treating atherosclerotic disease.
Related Concept Videos
lncRNA - Long Non-coding RNAs
Atherosclerosis I: Introduction
MicroRNAs
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Inflammation